Oliver Rath

List of Publications by Year
in descending order

25 papers	4,157 citations	361413 20 h-index	610901 24 g-index
25 all docs	25 docs citations	25 times ranked	8420 citing authors

#	Article	IF	Citations
1	MAP kinase signalling pathways in cancer. Oncogene, 2007, 26, 3279-3290.	5.9	2,473
2	Kinesins and cancer. Nature Reviews Cancer, 2012, 12, 527-539.	28.4	412
3	Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. Journal of Cell Science, 2009, 122, 425-435.	2.0	162
4	A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways. Oncogene, 2007, 26, 4571-4579.	5.9	141
5	Functional Roles of Multiple Feedback Loops in Extracellular Signal-Regulated Kinase and Wnt Signaling Pathways That Regulate Epithelial-Mesenchymal Transition. Cancer Research, 2010, 70, 6715-6724.	0.9	138
6	Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron and Fluorastrol. Journal of Medicinal Chemistry, 2010, 53, 5676-5683.	6.4	126
7	Raf Kinase Inhibitor Protein RKIP Enhances Signaling by Glycogen Synthase Kinase-3Î². Cancer Research, 2011, 71, 1334-1343.	0.9	124
8	RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Molecular BioSystems, 2011, 7, 928-941.	2.9	58
9	Relocation of Auroraâ€…B and Survivin from Centromeres to the Central Spindle Impaired by a Kinesinâ€Specific MKLPâ€1 Inhibitor. Angewandte Chemie - International Edition, 2010, 49, 8228-8231.	13.8	54
10	The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cellular Signalling, 2008, 20, 935-941.	3.6	49
11	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget, 2015, 6, 25619-25630.	1.8	48
12	Structural Insights into a Unique Inhibitor Binding Pocket in Kinesin Spindle Protein. Journal of the American Chemical Society, 2013, 135, 2263-2272.	13.7	44
13	Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Letters, 2006, 580, 6405-6412.	2.8	43
14	Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia, 2012, 26, 1842-1849.	7.2	38
15	Regulation of human myoblast differentiation by PEBP4. EMBO Reports, 2009, 10, 278-284.	4.5	37
16	Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity. Journal of Medicinal Chemistry, 2012, 55, 1511-1525.	6.4	37
17	Optimized S-Trityl-<scp>l</scp>-cysteine-Based Inhibitors of Kinesin Spindle Protein with Potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models. Journal of Medicinal Chemistry, 2013, 56, 1878-1893.	6.4	35
18	LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget, 2015, 6, 38469-38486.	1.8	34

#	Article	IF	Citations
19	Extracellular Signal-Regulated Kinase Regulates RhoA Activation and Tumor Cell Plasticity by Inhibiting Guanine Exchange Factor H1 Activity. Molecular and Cellular Biology, 2013, 33, 4526-4537.	2.3	30
20	Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models. Molecular BioSystems, 2010, 6, 2174.	2.9	24
21	Doing the methylene shuffle â€“ Further insights into the inhibition of mitotic kinesin Eg5 with S-trityl l-cysteine. European Journal of Medicinal Chemistry, 2012, 54, 483-498.	5.5	20
22	Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis. Journal of Natural Products, 2016, 79, 1576-1585.	3.0	16
23	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Translational Oncology, 2016, 9, 197-202.	3.7	10
24	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitorâ€“Resistant Clear Cell Renal Cell Carcinoma. Translational Oncology, 2017, 10, 304-310.	3.7	4
25	c-Myc is required for transformation of FDC-P1 cells by EGFRvIII. FEBS Letters, 2007, 581, 2549-2556.	2.8	0